Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Mayo Clinic
PRIMARY OBJECTIVE:
I. To evaluate immune profile of AML patients receiving venetoclax plus azacitidine induction chemotherapy.
SECONDARY OBJECTIVE:
I. To determine clinical responses based on immune infiltrated vs immune depleted subtypes of AML receiving azacitidine and venetoclax chemotherapy.
OUTLINE: This is an observational study.
Patients undergo blood sample collection and bone marrow aspirate on study. Patients' medical records are reviewed.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adults \> 18 yrs of age with diagnosis of acute myeloid leukemia who received azacitidine plus venetoclax chemotherapy
